Annotation Detail
Information
- Associated Genes
- TP53
- Associated Variants
-
TP53 DELETERIOUS MUTATION
TP53 DELETERIOUS MUTATION - Associated Disease
- chronic lymphocytic leukemia
- Source Database
- CIViC Evidence
- Description
- Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1481
- Gene URL
- https://civic.genome.wustl.edu/links/genes/45
- Variant URL
- https://civic.genome.wustl.edu/links/variants/222
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Chronic Lymphocytic Leukemia
- Evidence Direction
- Supports
- Drug
- Alemtuzumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 14726385
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Alemtuzumab | Sensitivity | true |